For example, muraglitazar, a dual PPARα/γ agonist, was taken through a comprehensivedevelopment program and demonstrated remarkable efficacy in lowering HbA1c aswell as improving lipid profile in T2DM patients. Here, PPARA is linked to type 2 diabetes mellitus.